CAMBRIDGE, Mass. — August 27, 2025 — Leads & Copy — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, will attend the H.C. Wainwright Global Investment Conference in New York City. Management is slated to present a company overview at 3:00 p.m. ET on September 8, 2025.
A webcast replay will be available on the Seres website approximately two hours after the event and will be archived for approximately 21 days.
Seres Therapeutics, Inc. (Nasdaq: MCRB) focuses on improving patient outcomes through novel live biotherapeutics. Seres developed and gained approval for VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has Breakthrough Therapy and Fast Track designations for allo-HSCT, and which has shown a reduction in bloodstream infections and related complications in a Phase 1b clinical study. The Company intends to evaluate SER-155 and other candidates in medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Source: Seres Therapeutics, Inc.
